摘要
天津是传统医药和医疗强市,长期重视生物医药产业发展,但与国内其他省份比较,天津市生物医药行业存在着综合实力较弱、原始创新能力不强、细分领域发展不充分等问题。提出发挥科研和产业优势,抓住发展机遇,围绕国家战略布局狠抓关键技术和产品;增强政府对鼓励创新研发、落实资助政策的支持力度;加强区域合作,真正实现全市生物医药行业高质量全面发展,为经济发展和人民健康谋福利。
As a traditional and competitive city in the bio-pharmaceutical industry,Tianjin pays much attention to the industrial development. Compared with other provinces,Tianjin has its disadvantages. The industry's comprehensive strength is weak,the original innovation ability is not strong,and the niche industry is insufficiently developed. We suggest that Tianjin should take advantage of the overall strength of research and industry base,and seize the opportunity and improve product quality. Besides,supportive funding policies should also be made to lead innovative activities. Only in this way can we fulfill a high quality development and benefit the people.
引文
[1]黄国琼.生命科学发展前沿对高等医学教育的影响与对策研究[D].重庆:第三军医大学,2006.
[2]万丽梅,湛晶心.资本市场需要怎样的“独角兽”[J].中国金融,2018(12):75-76.
[3]褚淑贞,王恩楠,都兰娜.我国医疗器械产业发展现状、问题及对策[J].中国医药工业杂志,2017,48(6):930-935.
[4]周立群,周晓波.京津沪生物医药产业比较研究及对天津的启示[J].天津大学学报:社会科学版,2015,17(6):481-485.
[5]高青松,李婷.“中国制造2025”研究进展及评述[J].工业技术经济,2018,37(10):59-66.
[6]冯昊,潘悦,雷霆,等.北京市开展仿制药一致性评价的实践及进展[J].中国医药工业杂志,2017,48(12):1807-1817.